Pediatrix Medical Group Inc 2026年季度报告

For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☐Emerging growth company☐ Large accelerated filer☑Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☑On May 1, 2026, the registrant had outstanding 82,121,911 shares of Common Stock, par value $.01 per share. Pediatrix Medical Group, Inc. INDEX PART I - FINANCIAL INFORMATION Item 1.Financial Statements3Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)3Consolidated Statements of Income and Comprehensive Income for the Three MonthsEndedMarch 31, 2026 and 2025 (Unaudited)4Consolidated Statements of Shareholders' Equity for the Three Months EndedMarch 31, 2026 and 2025 (Unaudited)5Consolidated Statements of Cash Flows for the Three Months EndedMarch 31, 2026 and 2025 (Unaudited)6Notes to Consolidated Financial Statements (Unaudited)7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations13Item 3.Quantitative and Qualitative Disclosures About Market Risk19Item 4.Controls and Procedures19PART II - OTHER INFORMATIONItem 1.Legal Proceedings20Item 1A.Risk Factors20Item 2.Unregistered Sales of Equity Securities and Use of Proceeds20Item 5.Other Information20Item 6.Exhibits22SIGNATURES23 Pediatrix Medical Group, Inc.Consolidated Balance Sheets(in thousands, except share data)(Unaudited) Pediatrix Medical Group, Inc.Consolidated Statements of Income and Comprehensive Income(in thousands, except per share data)(Unaudited) Pediatrix Medical Group, Inc.Consolidated Statements of Shareholders’ Equity(in thousands)(Unaudited) Pediatrix Medical Group, Inc.Consolidated Statements of Cash Flows(in thousands)(Unaudited) Pediatrix Medical Group, Inc.Notes to Consolidated Financial StatementsMarch 31, 2026(Unaudited) 1.Basis of Presentation: The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicableto interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the UnitedStates of America (“GAAP”) for complete financial statements. In the opinion of management, these financial statements include alladjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. Thefinancial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, “PMG”)together with the accounts of PMG’s affiliated business corporations or professional associations, professional corporations, limitedliabilitycompanies and partnerships(the“affiliated professional contractors”).Certain subsidiaries of PMG have contractualmanagement arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services incertain states. The terms “Pediatrix” and the “Company” refer collectively to Pediatrix Medical Group, Inc., its subsidiaries and theaffiliated professional contractors. The Company is a party to a joint venture in which it owns a 37.5% economic interest. The Company accounts for this jointventure under the equity method of accounting because the Company exercises significant influence over, but does not control, thisentity. The consolidated results of operations for